LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Final CHAMPION-NMOSD Results.Neurol Neuroimmunol Neuroinflamm | PMID 42441931PMC13372128 | 2026-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Premature Termination of the Phase III SALAMANDER Trial of REX-001, an Autologous Bone Marrow Cell Therapy, for Chronic Limb Ischemia in Diabetic Patients: Insights and Outcomes.Ann Vasc Surg | PMID 42119725无 PMCID | 2026-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data From a Randomized Phase III Trial.Ther Drug Monit | PMID 41622540PMC13344386 | 2026-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Radiological classification of non-anastomotic biliary strictures after liver transplantation.Eur Radiol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41995739PMC13342394 | 2026-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial.Diabetes Obes Metab | PMID 42219225PMC13341324 | 2026-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer's Disease: Timing and Duration of Adverse Events.Drug Saf | PMID 41961243PMC13354622 | 2026-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study.Diabetes Obes Metab | PMID 42108080PMC13341361 | 2026-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III randomized placebo-controlled trial on repurposing olanzapine for prevention of radiotherapy induced nausea and vomiting (RINV): CTRI/2022/01/039723.Radiother Oncol | PMID 42119640无 PMCID | 2026-Aug | 0.85 | The study meets criteria for oncology, human, randomized, phase III, drug intervention, and original result, but fails the critical time-to-event endpoint criterion. | 待处理 |
| Acute and long-term toxicity profiles and final oncologic outcomes in the phase III ARTFORCE trial.Radiother Oncol | PMID 42119642无 PMCID | 2026-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Pelvic nodes ultra-hypo fractionated versus conventionally fractionated IMRT with HDR brachytherapy in prostate cancer: interim analysis of a collaborative multi-institutional non-inferiority phase 3 trial (PCS-XI, NCT05820633).Radiother Oncol | PMID 42134662无 PMCID | 2026-Aug | 0.85 | The study is a Phase III randomized trial in oncology with human subjects and original interim results. However, it is excluded because it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) in the provided abstract. The reported outcomes focus on toxicity and patient-reported outcomes, not the required time-to-event efficacy endpoint. | 待处理 |
| Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis.Clin Pharmacol Ther | PMID 42175562PMC13339437 | 2026-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study.Diabetes Obes Metab | PMID 42186210PMC13341321 | 2026-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study.Diabetes Obes Metab | PMID 42219226PMC13341390 | 2026-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Delgocitinib cream for adolescents with moderate to severe chronic hand eczema (DELTA TEEN): a multicentre, double-blind, phase 3 randomised controlled trial.Lancet Child Adolesc Health | PMID 42235562无 PMCID | 2026-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of a pentavalent meningococcal MenABCWY vaccine in healthy adolescents and young adults: a phase 3, multicountry, randomised, observer-blinded, active-controlled non-inferiority trial.Lancet Child Adolesc HealthPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42314722无 PMCID | 2026-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.Lancet Gastroenterol Hepatol入排复审未纳入:The report presents preplanned Phase 2 results from a Phase 2-3 trial that was stopped and did not progress to Phase 3. The primary endpoint was objective response rate (RECIST v1.1), not a time-to-event endpoint like OS or PFS. While it is an oncology RCT with drug intervention, it fails the criteria for Phase 3/definitive trial and time-to-event primary efficacy endpoint. | PMID 42330996无 PMCID | 2026-Aug | 0.85 | The report presents preplanned Phase 2 results from a Phase 2-3 trial that was stopped and did not progress to Phase 3. The primary endpoint was objective response rate (RECIST v1.1), not a time-to-event endpoint like OS or PFS. While it is an oncology RCT with drug intervention, it fails the criteria for Phase 3/definitive trial and time-to-event primary efficacy endpoint. | 无 KM 图 |
| Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42269244无 PMCID | 2026-Jul-26 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs.Gut LiverPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42325011无 PMCID | 2026-Jul-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Single, Interpretable Vocal Biomarker for Enriching Antipsychotic Clinical Trials.Biol Psychiatry疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41419191无 PMCID | 2026-Jul-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Pharmacologic de-escalation of dexamethasone during weekly paclitaxel: a randomized phase III trial evaluating safety, endocrine effects, and quality of life.Cancer Chemother Pharmacol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:CONSORT/入组流程图;Fig. 3:身体组成变化图;Fig. 4:生活质量量表图。 | PMID 42439956PMC13364796 | 2026-Jul-13 | 0.85 | The trial is a randomized phase III study in human oncology with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint (like OS, PFS, DFS) with Kaplan-Meier or hazard ratio analysis. The oncologic outcomes mentioned (recurrence and disease-related mortality) are described only as similar in descriptive analyses without formal time-to-event statistical reporting, and the study's primary focus is on safety and quality of life. | 无 KM 图 |
| Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42259339无 PMCID | 2026-Jul-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Longitudinal Disease Progression Model Characterizing Endoscopic Response and Remission in Crohn's Disease.J Pharmacokinet Pharmacodyn入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 42436336PMC13356052 | 2026-Jul-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO).MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42296968无 PMCID | 2026-Jul-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41812190无 PMCID | 2026-Jul-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42149993无 PMCID | 2026-Jul-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42418774无 PMCID | 2026-Jul-09 | 0.95 | The study is a randomized Phase III trial of a drug (setmelanotide) for acquired hypothalamic obesity, which is not a human malignant neoplasm. The primary and secondary endpoints are continuous measures of change (BMI, hunger score), not time-to-event outcomes required for the oncology Kaplan-Meier digitization cohort. | 无 KM 图 |
| Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42418775无 PMCID | 2026-Jul-09 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.Breast Cancer Res Treat疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42420599无 PMCID | 2026-Jul-08 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.J Am Heart Assoc入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 42333640无 PMCID | 2026-Jul-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Intra-Arterial thrombolysis after SUCCESSful angiographic recanalization in acute large-vessel occlusion stroke of the anterior circulation (IA-SUCCESS): a multicentre, randomised, clinical trial protocol.Eur Stroke J入排复审未纳入:方案论文未报告临床试验结果。 | PMID 42439416PMC13358873 | 2026-Jul-06 | 0.97 | 方案论文未报告临床试验结果。 | 无 KM 图 |
| Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study).Jpn J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41968990无 PMCID | 2026-Jul-06 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.Signal Transduct Target Ther | PMID 42402625PMC13334029 | 2026-Jul-06 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42251856无 PMCID | 2026-Jul-04 | 0.95 | The record is a phase 3 randomized trial with a drug intervention and original results, but it does not meet the core eligibility criteria. The study is not in oncology (it's for type 2 diabetes) and its primary/secondary endpoints are not time-to-event (they are changes in HbA1c and bodyweight, which are continuous variables). | 无 KM 图 |
| Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42384869无 PMCID | 2026-Jul-02 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42384870无 PMCID | 2026-Jul-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Factors Associated With Perfluorohexyloctane Treatment Response in Dry Eye Disease Associated With Meibomian Gland Dysfunction.CorneaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40632907无 PMCID | 2026-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effects of Nutritional Interventions on Quality of Life in Patients with Nasopharyngeal Carcinoma Undergoing Radiation Therapy Based on Dynamic Nutritional Risk Screening and Assessment: An Open-Label Single-Center Randomized Phase 3 Trial.Int J Radiat Oncol Biol PhysPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41325872无 PMCID | 2026-Jul-01 | 0.95 | The study is a randomized Phase III trial in oncology with original results, but it is excluded because the intervention is non-drug-only (nutritional support) and the primary endpoint is quality-of-life, not a time-to-event efficacy endpoint as required. | 无 KM 图 |
| OnabotulinumtoxinA for Platysma Prominence: Safety and Efficacy Results from a Phase 3 Open-Label Repeat Treatment Study.Plast Reconstr Surg入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41329600PMC13290051 | 2026-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.Haematologica | PMID 41568521PMC13317827 | 2026-Jul-01 | 0.85 | The report is from a randomized Phase III oncology trial with a drug intervention, but it does not present a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The main outcomes are patient-reported outcomes and quality of life, which are secondary/exploratory analyses. | 已完成 |
| Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials.J Am Soc Nephrol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41604274PMC13337159 | 2026-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants.Int Clin PsychopharmacolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41749468无 PMCID | 2026-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Remimazolam Tosylate versus Propofol for Sedation of Postoperative Mechanically Ventilated Patients in Intensive Care Units: A Multicenter, Randomized, Single-blind, Noninferiority, Phase 3 Trial.AnesthesiologyPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41855428无 PMCID | 2026-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy).Am J Respir Crit Care Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:非 KM 图;Figure 3:AI 判定为 other。 | PMID 42148495PMC13318230 | 2026-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Ecopipam for Tourette Syndrome: A Phase 3 Randomized Clinical Trial.JAMA Neurol | PMID 42189524PMC13213590 | 2026-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages: Post Hoc Analysis of the FIDELITY Randomized Clinical Trials.JAMA CardiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42234437PMC13234752 | 2026-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19.Crit Care Explor疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:非 KM 图。 | PMID 42329789PMC13290196 | 2026-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Robotic versus Open Pancreatoduodenectomy (PORTAL): multicentre, single masked, phase 3, non-inferiority randomised controlled trial.BMJPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42386316无 PMCID | 2026-Jul-01 | 0.95 | The trial is a well-conducted, phase 3, randomized, oncology (pancreatic cancer) trial with a primary time-to-event endpoint (time to functional recovery). However, it is excluded because it does not involve a drug-containing intervention (the comparison is between two surgical approaches) and the primary endpoint is not a standard oncologic efficacy endpoint like OS or PFS, but rather a surgical recovery outcome. Therefore, it does not meet the criteria for inclusion in a cohort focused on drug intervention efficacy. | 无 KM 图 |
| Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous Urticaria.Clin Transl Sci已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。 | PMID 42443720PMC13364750 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.Diabetes Obes Metab入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 42017294PMC13243934 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Intravenous Meloxicam Versus Ketorolac for Pain Control Following Total Joint Arthroplasty: A Double-Blind Randomized Controlled Trial.J ArthroplastyPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41167538无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
第 1 / 141 页
下一页